Pharmacokinetic Study of Dexmedetomidine After Intra-nasal Dosing in Children

• Status: Completed
• Trial end date: 2018-04-01
• Target enrollment: 0
• Participant gender: All

Summary

This research study is examining the absorption of the sedative dexmedetomidine (DEX) in the blood when given by nasal spray. The study will help us determine the best dosing amount for children undergoing sedation or anesthesia with DEX.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Children's Hospital Medical Center, Cincinnati
• Treatments: Dexmedetomidine

Criteria

Inclusion Criteria:

• Children aged 6 - 48 months (inclusive) scheduled to receive anesthesia for elective cardiac surgery.

• The subject must be a candidate to receive DEX. A physician member of the Division of Cardiac Anesthesiology, not involved in the study, will make this decision.

• The subject's legally authorized representative has given written informed consent to participate in the study.

Exclusion Criteria:

• Post-natal age (PNA) < 6 months

• The subject is allergic to or has a contraindication to DEX

• Severely depressed ventricular function (ejection fraction 30% or less) on preoperative echocardiogram

• The subject has high risk cardiac conduction system disease at the discretion of the attending anesthesiologist or cardiologist.

• The subject has a hemodynamically significant coarctation or other left heart outflow obstruction

• The subject has received digoxin, beta-adrenergic antagonist, or calcium-channel antagonist on the day of the study

• The subject has received DEX within 1 week of the study date (information obtained from: parent or Medical record)

• Subject have nasal/respiratory symptoms which in the opinion of the Principal investigator, may affect intranasal drug absorption.